SCYX Q3 2023 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2M+13.1% YoY

Gross Profit

$1M78.5% margin

Operating Income

-$10M-573.4% margin

Net Income

-$2M-99.8% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-98.7%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$12M

Stock-Based Comp.

$632,000

Balance Sheet

Total Assets

$149M

Total Liabilities

$57M

Stockholders' Equity

$92M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+13.1%
Gross Profit	$1M	$1M	+1.0%
Operating Income	-$10M	-$22M	+53.7%
Net Income	-$2M	-$30M	+94.1%

Revenue Segments

License and Service

$2M135%

Product

-$614,000-35%